Disable ads (and more) with a membership for a one time $4.99 payment
Belatacept is indicated for patients with what specificity?
EBV seropositive patients only
Patients with no history of autoimmune diseases
Patients with a history of diabetes
EBV seronegative patients only
The correct answer is: EBV seropositive patients only
Belatacept is a medication used for immunosuppression in patients who have had a kidney transplant. The drug works by blocking certain immune cells to prevent organ rejection. However, belatacept can increase the risk of developing post-transplant lymphoproliferative disorder (PTLD), a serious condition that is associated with the Epstein-Barr virus (EBV). Therefore, belatacept is specifically indicated for EBV seropositive patients to monitor and manage the risk of PTLD. This is why the correct answer is A. Options B, C, and D are incorrect because belatacept is not indicated based on the absence or presence of autoimmune diseases, history of diabetes, or EBV seronegative status. The primary consideration for the use of belatacept is the patient's EBV seropositive status due to the potential risk of PTLD associated with this medication.